Clinical trials: Mammary Tumor
Breast Cancer
Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors
A single--blind, randomized, placebo--controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving aromatase inhibitors as adjuvant treatment.
- Trial name
- BONADIUV (NCT02616744)
- Testing
- Ibandronic acid
- Where
- Italy
- Volunteers
- 171 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Breast Cancer
Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer
Oncotype DX® is likely to become more widely used in Europe as well as in Switzerland. The test is currently not reimbursed by the Swiss health insurances.
- Trial name
- NCT01926964
- Where
- 19 sites in Switzerland
- Volunteers
- 229 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Study of Effects of Dao-yin Exercise on the Patients With Breast Cancer Post Operation and Receiving Adjuvant Chemotherapy
This is a retrospective registration of a study that evaluated whether a traditional Dao-yin (mind-body exercise), called Shangshou Dao-yin, could improve sleep quality, Chinese medicine body constitution, and quality of life in…
- Trial name
- NCT07262099
- Testing
- Shangshou Dao-yin
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Breast Cancer Female, Breast Cancer
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1)…
- Conditions
- Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer
- Trial name
- NCT06439693
- Testing
- Nab-Paclitaxel, Paclitaxel, Docetaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Neoplasm, Stage III Pancreatic Cancer
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with…
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02897375
- Testing
- Carboplatin, Cisplatin, Palbociclib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Emory University
Triple Negative Breast Cancer
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
- Trial name
- NCT07332975
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pittsburgh
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Breast Cancer Surgery
Vicryl Plus and Monocryl Plus in Breast Surgery
This is a randomised pilot study comparing conventional sutures (Vicryl and Monocryl) with antiseptic coated equivalents (Vicryl plus andf Monocryl plus) in elective breast surgery.
- Trial name
- NCT00830271
- Testing
- Vicryl plus and Monocryl plus, wound closure with Vicryl and Monocryl
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cardiff and Vale University Health Board
Breast Cancer, Solid Tumor, Adult
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/HER2…
- Trial name
- NCT04946864
- Testing
- APG-2575, Palbociclib
- Where
- 7 sites in United States, China
- Volunteers
- 65 people
- Sponsor
- Ascentage Pharma Group Inc.
Breast Cancer
Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer
The study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of standard chemotherapy versus standard chemotherapy followed by capecitabine as prolonged postoperative adjuvant…
- Trial name
- NCT02842099
- Testing
- TA or TAC, X
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype.
- Conditions
- Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
- Trial name
- NCT06062498
- Testing
- elacestrant, palbociclib, abemaciclib, ribociclib
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Northwestern University
Breast Cancer, Solid Tumor
Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
The goal of NEOPRO-SIT is to establish and evaluate a neoadjuvant prehabilitation program comprised of targeted exercise therapy and structured psycho-oncological support in patients with solid tumors.
- Trial name
- NEOPRO-SIT (NCT07464457)
- Testing
- Prehabilitation, standard of care
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Priv.-Doz. Dr. med. Philipp Lenz
Breast Cancer
Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies such as HuHMFG1 can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00096057
- Testing
- monoclonal antibody HuHMFG1
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer Females, Oncology
Effects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
Introduction: The significant improvement in breast cancer survival, largely attributable to biomedical and technological progress, makes it increasingly necessary to investigate the secondary effects linked to this pathology.
- Trial name
- NCT07165912
- Testing
- Health Education Program, Individual Cognitive Training Program, Group training program
- Where
- 2 sites in Spain
- Volunteers
- 75 people
- Sponsor
- University of Salamanca
Breast Cancer, Knowledge, Attitudes, Practice
Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material
The goal of this clinical trial is to evaluate if a customizable support material allows to improve the knowledge about the stage and subtype of the disease, as well as the indicated treatments, in comparison with a…
- Conditions
- Breast Cancer, Knowledge, Attitudes, Practice, Patient Empowerment, Patient Satisfaction
- Trial name
- NCT05798312
- Testing
- Customizable support material, Non-customizable support material
- Where
- Mexico
- Volunteers
- 125 people
- Sponsor
- Medicos e Investigadores en la Lucha contra el Cancer de Mama
Breast Cancer
Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)
In this study, effects of γδT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
- Trial name
- NCT02418481
- Testing
- DC-CIK, γδ T Cell, Combination
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Breast Neoplasms
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive.
- Trial name
- NCT02510781
- Testing
- Epirubicin, Docetaxel, Trastuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hospital Affiliated to Military Medical Science, Beijing
HER2-positive Breast Cancer, HER-2 Protein Overexpression
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
- Conditions
- HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
- Trial name
- NCT05511844
- Testing
- ORM-5029
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Orum Therapeutics USA, Inc.
Breast Cancer, Insomnia
Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)
In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.
- Trial name
- NCT06006299
- Testing
- transauricular Vagus Nerve Stimulation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.